A Cyclic Peptidic Serine Protease Inhibitor: Increasing Affinity by Increasing Peptide Flexibility

Peptides are attracting increasing interest as protease inhibitors. Here, we demonstrate a new inhibitory mechanism and a new type of exosite interactions for a phage-displayed peptide library-derived competitive inhibitor, mupain-1 (CPAYSRYLDC), of the serine protease murine urokinase-type plasminogen activator (uPA). We used X-ray crystal structure analysis, site-directed mutagenesis, liquid state NMR, surface plasmon resonance analysis, and isothermal titration calorimetry and wild type and engineered variants of murine and human uPA. We demonstrate that Arg6 inserts into the S1 specificity pocket, its carbonyl group aligning improperly relative to Ser195 and the oxyanion hole, explaining why the peptide is an inhibitor rather than a substrate. Substitution of the P1 Arg with novel unnatural Arg analogues with aliphatic or aromatic ring structures led to an increased affinity, depending on changes in both P1 - S1 and exosite interactions. Site-directed mutagenesis showed that exosite interactions, while still supporting high affinity binding, differed substantially between different uPA variants. Surprisingly, high affinity binding was facilitated by Ala-substitution of Asp9 of the peptide, in spite of a less favorable binding entropy and loss of a polar interaction. We conclude that increased flexibility of the peptide allows more favorable exosite interactions, which, in combination with the use of novel Arg analogues as P1 residues, can be used to manipulate the affinity and specificity of this peptidic inhibitor, a concept different from conventional attempts at improving inhibitor affinity by reducing the entropic burden.

[1]  F. Mulder,et al.  Bicyclic Peptide Inhibitor of Urokinase‐Type Plasminogen Activator: Mode of Action , 2013, Chembiochem : a European journal of chemical biology.

[2]  P. Leiman,et al.  Bicyclic peptide ligands pulled out of cysteine-rich peptide libraries. , 2013, Journal of the American Chemical Society.

[3]  Giuseppe Zanotti,et al.  Bicyclic peptide inhibitor reveals large contact interface with a protease target. , 2012, ACS chemical biology.

[4]  Mingdong Huang,et al.  Elucidation of the Contribution of Active Site and Exosite Interactions to Affinity and Specificity of Peptidylic Serine Protease Inhibitors Using Non-Natural Arginine Analogs , 2011, Molecular Pharmacology.

[5]  C. Weydert,et al.  The binding mechanism of a peptidic cyclic serine protease inhibitor. , 2011, Journal of molecular biology.

[6]  F. Poulsen,et al.  Random coil chemical shift for intrinsically disordered proteins: effects of temperature and pH , 2011, Journal of biomolecular NMR.

[7]  B. Furie,et al.  Structural Basis for Recognition of Urokinase-type Plasminogen Activator by Plasminogen Activator Inhibitor-1* , 2011, The Journal of Biological Chemistry.

[8]  G. Salvesen,et al.  Emerging principles in protease-based drug discovery , 2010, Nature Reviews Drug Discovery.

[9]  Michele Bernasconi,et al.  Furin Targeted Drug Delivery for Treatment of Rhabdomyosarcoma in a Mouse Model , 2010, PloS one.

[10]  Hanne Mørck Nielsen,et al.  Challenges in Delivery of Biopharmaceuticals; the Need for Advanced Delivery Systems , 2009 .

[11]  Knud J. Jensen,et al.  Peptide and protein design for biopharmaceutical applications , 2009 .

[12]  H. Kessler,et al.  Design of Cyclic Peptides , 2009 .

[13]  G. Winter,et al.  Phage-encoded combinatorial chemical libraries based on bicyclic peptides. , 2009, Nature chemical biology.

[14]  A. Bax,et al.  TALOS+: a hybrid method for predicting protein backbone torsion angles from NMR chemical shifts , 2009, Journal of biomolecular NMR.

[15]  P. Andreasen,et al.  A cyclic peptidylic inhibitor of murine urokinase-type plasminogen activator: changing species specificity by substitution of a single residue. , 2008, The Biochemical journal.

[16]  C. Yuan,et al.  Structural basis of specificity of a peptidyl urokinase inhibitor, upain-1. , 2007, Journal of structural biology.

[17]  A. Brunger Version 1.2 of the Crystallography and NMR system , 2007, Nature Protocols.

[18]  Kevin Cowtan,et al.  research papers Acta Crystallographica Section D Biological , 2005 .

[19]  X. Puente,et al.  Human and mouse proteases: a comparative genomic approach , 2003, Nature Reviews Genetics.

[20]  L. Hedstrom Serine protease mechanism and specificity. , 2002, Chemical reviews.

[21]  Dirk Labudde,et al.  A software tool for the prediction of Xaa-Pro peptide bond conformations in proteins based on 13C chemical shift statistics , 2002, Journal of biomolecular NMR.

[22]  P. Andreasen,et al.  The plasminogen activation system in tumor growth, invasion, and metastasis , 2000, Cellular and Molecular Life Sciences CMLS.

[23]  M. Duffy,et al.  The urokinase‐type plasminogen activator system in cancer metastasis: A review , 1997, International journal of cancer.

[24]  C. Ponting,et al.  The crystal structure of the catalytic domain of human urokinase-type plasminogen activator. , 1995, Structure.

[25]  Collaborative Computational,et al.  The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.

[26]  K. Danø,et al.  Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor. , 1991, The Journal of biological chemistry.

[27]  B. Furie,et al.  The molecular basis of blood coagulation , 1988, Cell.

[28]  K. Wüthrich NMR of proteins and nucleic acids , 1988 .

[29]  X. Puente,et al.  Protease Genomics and the Cancer Degradome , 2008 .

[30]  W. Delano The PyMOL Molecular Graphics System , 2002 .

[31]  Z. Otwinowski,et al.  Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.

[32]  E. Ruoslahti,et al.  Peptides in cell adhesion research. , 1994, Methods in enzymology.

[33]  K. Danø,et al.  Plasminogen activators, tissue degradation, and cancer. , 1985, Advances in cancer research.